In the BioHarmony Drug Report Database

"Preview" Icon

Givosiran sodium

Givlaari (givosiran sodium) is an oligonucleotide pharmaceutical. Givosiran sodium was first approved as Givlaari on 2019-11-20. It has been approved in Europe to treat hepatic porphyrias. Givlaari’s patents are valid until 2034-10-03 (FDA).

 

Trade Name

 

Givlaari
 

Common Name

 

givosiran sodium
 

ChEMBL ID

 

CHEMBL4594265
 

Indication

 

hepatic porphyrias
 

Drug Class

 

Image (chem structure or protein)

Givosiran sodium structure rendering